Immune Checkpoint Drugs in Oncology: Analytical Tool

  • ID: 3829949
  • Report
  • Region: Global
  • Bioseeker
1 of 2
Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals from a business development, drug development or investment perspective.

The Analytical Tools have proven their worth to our clients in oncology for almost two decades in their capacities covering:
- Target Scouting
- Early & Late Stage Pipeline Analysis
- Biomarker/Companion Diagnostic Analysis
- Deal & Alliance Analysis
- Combination Therapy Analysis
- Indication Selection & Expansion Analysis
- First-in-Class Analysis
- Drug Repositioning
- Pipeline Analysis by Targeted Pathways

Analytical Tools transform your computer’s desktop into a high capacity workbench within your area of choice. Even before launching this desktop app you have already eliminated hundreds of hours of work needed to discover, process and piece together the thousands of sources that our team of oncology dedicated and highly experienced contents specialists have done on your behalf. It covers more than 122 companies plus partners who are today developing 252 immune checkpoint drugs in oncology drugs where of 227 are active in 835 developmental projects in cancer across 71 different targets. The Analytical Tool and its contents are yours to keep and data can be easily exported into Excel format for mixing with your own proprietary information.

Let our expertise work for you
While executing some of your daily tasks in our Analytical Tools you will benefit from almost two decades of our experience in perfecting features and analysis, allowing you to easily create breakdowns, tables, graphs and exports for your reports, presentations and conference attendance via our easy to use point and click interface.

Support and inspiration at your finger-tips
You also have access to a great selection of How-to Training Videos showing best practice approaches to aspects such as competitive pipeline analysis right through to many real world case examples put forward by other users of our Analytical Tools.

A tool to grow with and keep you informed
Unlike a static report which just represents a particular snapshot in time, all of the Analytical Tools come with one year of free online access to twice-weekly updates in both contents and features , pipeline alerts and online support. You can choose to renew your access to these updates and support on a yearly basis or go completely online with our industry leading full service platform, 1stOncology.

Your key to accessing the 1stOncology Newsdesk
As a special bonus, your Analytical Tool unlocks lifetime(*) access to the 1stOncology Newdesk! This service, which is normally reserved for full 1stOncology users only, is a live stream of breaking news within the oncology industry. Updated every 5 minutes, you can tune in to specific channels such as Social Media, Clinical Trials, Intellectual Property, Financial data and Press Releases. This is a great tool to ensure your surveillance of your area of interest is complete.

Did you know?
The Targeting Immune Checkpoints in Cancer Immunotherapy: Drug Pipeline Update is the most up to date and comprehensive pipeline review and competitive assessment you can get on this hot and fast moving area in cancer immunology. There are two sides of immune checkpoint control; those which activate and those which inhibit T-cell activation. The Targeting Immune Checkpoints in Cancer Immunotherapy: Drug Pipeline Update covers both sides extensively.
There are currently four approved immune check point inhibitors, namely Yervoy (ipilimumab), Opdivo (nivolumab), Keytruda (pembrolizumab) and Tecentriq (atezolizumab). Bristol-Myers Squibb's Yervoy, a CTLA4 targeting antibody, was first to be approved in 2011 for the treatment of patients with unresectable or metastatic melanoma. In 2014 came two more approvals, Opdivo was first approved in Japan through Ono Pharmaceutical and later followed by Merck & Co’s Keytruda. Both Keytruda and Opdivo are PD-1 inhibitors and were first approved for treatment of melanoma. In 2016 Roche's PD-L1 inhibitor Tecentriq was granted an accelerated approval by the US FDA for the treatment of people with locally advanced or metastatic urothelial carcinoma. Collectively, immune checkpoint inhibitors are currently approved for the treatment of five different cancer types: bladder cancer, Hodkin's lymphoma, melanoma, non-small cell lung cancer and renal cancer. The world-wide Q2 2016 sales for these drugs were; Yervoy (241m USD), Opdivo (840m USD), Keytruda (314m USD) and Tecentriq (19m CHF).
The Analytical Tools are a longstanding series of products powering decision making in oncology since 1999. Transform your computer’s desktop to a dedicated oncology workbench today! Request sample pages or order here to ensure you are not missing out on what you need to know.

System Requirements
- Operating system: Windows (2000/XP/Vista/7/10) for Desktop App and Mac OSX access only via our online service.
- Browser Application (Internet Explorer, FireFox, Chrome or Safari))
- Internet access (to access related internet resources)
(*) In this context, lifetime access refers to the full period of time that the provider offer a Newsdesk product or similar news based service.
Note: Product cover images may vary from those shown
2 of 2


3 of 2
Note: Product cover images may vary from those shown